Randomized, controlled study of the effects of raloxifene on high sensitivity C-reactive protein and serum lipids

Archives of Gynecology and Obstetrics

Volumn 283, Issue 1, 2011, Pages 71-77

  Oztas, Efser ^a   Kurtay, Gulay ^b  

^a UFUK UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

C reactive protein; Lipids; Menopause; Raloxifene

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RALOXIFENE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OPEN STUDY; POSTMENOPAUSE; PRIMARY PREVENTION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL; FEMALE; HUMANS; LIPIDS; MIDDLE AGED; POSTMENOPAUSE; RALOXIFENE; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 78751591701     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-009-1292-9     Document Type: Article

References (37)

1. DJ Lerner WB Kannel 1986 Patterns of coronary heart disease morbidity and mortality in the sexes: a 26 year follow-up of Framingham population Am J Heart 111 383 390 1:STN:280:DyaL287is12mtA%3D%3D 10.1016/0002-8703(86)90155-9 (Pubitemid 16107280)
2. C Gohlke-Barwolf 2000 Coronary artery disease-is menopause a risk factor? Basic Res Cardiol 95 Suppl 1 77 83 10.1007/s003950070014
3. Heart, Estrogen/progestin Replacement Study (HERS) Research Group 1998 Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women JAMA 280 7 605 613 10.1001/jama.280.7.605 (Pubitemid 28502636)
4. Heart, Estrogen/progestin Replacement Study (HERS) Research Group 2002 Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II) JAMA 288 1 49 57 10.1001/jama.288.1.49
5. N Cherry K Gilmour P Hannaford 2002 Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial Lancet 360 9350 2001 2008 1:CAS:528:DC%2BD38Xps12qs7c%3D 10.1016/S0140-6736(02) 12001-0 12504395 (Pubitemid 36026578)
6. Writing Group For The Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial JAMA 288 3 321 333 10.1001/jama.288.3.321
7. The Women's Health Initiative Steering Committee 2004 Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 291 14 1701 1712 10.1001/jama.291.14.1701 (Pubitemid 38489892)
8. R Ross 1999 Atherosclerosis-an inflammatory disease N Engl J Med 340 115 126 1:STN:280:DyaK1M%2FptFSqtQ%3D%3D 10.1056/NEJM199901143400207 9887164 (Pubitemid 29054847)
9. GK Hanson 2005 Inflammation, atherosclerosis, and coronary artery disease N Engl J Med 352 1685 1695 10.1056/NEJMra043430 (Pubitemid 40530235)
10. J Fan T Watanabe 2003 Inflammatory reactions in the pathogenesis of atherosclerosis J Atheroscler Thromb 10 63 71 1:CAS:528:DC%2BD3sXksFOlurc%3D 12740479
11. PM Ridker M Cushman MJ Stampfer RP Tracy CH Hennekens 1999 Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men N Engl J Med 336 14 973 979 10.1056/NEJM199704033361401
12. PM Ridker RJ Glynn CH Hennekens 1998 C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction Circulation 97 20 2007 2011 1:STN:280:DyaK1c3nt1Slsg%3D%3D 9610529
13. PM Ridker CH Hennekens JE Buring N Rifai 2000 C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women N Engl J Med 342 836 843 1:CAS:528:DC%2BD3cXisVensrs%3D 10.1056/NEJM200003233421202 10733371 (Pubitemid 30165206)
14. PM Ridker N Rifai L Rose JE Buring NR Cook 2000 Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events N Engl J Med 347 1557 1565 10.1056/NEJMoa021993
15. NR Cook JE Buring PM Ridker 2006 The effect of including C-reactive protein in cardiovascular risk prediction models for women Ann Intern Med 145 21 29 1:CAS:528:DC%2BD28XnslKhtL4%3D 16818925
16. A Saitta N Morabito N Frisina 2001 Cardiovascular effects of raloxifene hydrochloride Cardiovasc Drug Rev 19 1 57 74 1:CAS:528:DC%2BD3MXjtVKkt7g%3D 10.1111/j.1527-3466.2001.tb00183.x 11314601
17. BW Walsh DA Cox A Sashegyi 2001 Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women Am J Cardiol 88 7 825 828 1:CAS:528:DC%2BD3MXnt1Shtb8%3D 10.1016/S0002-9149(01)01865-3 11589863
18. T Yasui H Uemura S Hyodo M Yamada S Yamamoto M Maegawa N Tsuchiya M Noguchi M Yuzurihara Y Kase M Irahara 2009 Raloxifene reduces circulating levels of interleukin-7 and monocyte chemoattractant protein-1 in postmenopausal women Atherosclerosis 204 2 471 475 1:CAS:528:DC%2BD1MXmtl2lt70%3D 10.1016/j.atherosclerosis.2008.09.014 18976766
19. E Barrett-Connor D Grady A Sashegyi PW Anderson DA Cox K Hoszowski P Rautaharju KD Harper 2002 Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial JAMA 287 7 847 857 1:CAS:528: DC%2BD38XhsVGitb8%3D 10.1001/jama.287.7.847 11851576
20. KA Griffiths MA Sader MR Skilton 2003 Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease J Am Coll Cardiol 42 4 698 704 1:CAS:528:DC%2BD3sXnsFerurk%3D 10.1016/S0735-1097(03)00776-9 12932604 (Pubitemid 37000188)
21. AL Eilertsen L Sandvik B Steinsvik PM Sandset 2008 Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers J Thromb Haemost 6 6 928 934 1:CAS:528:DC%2BD1cXotFaqtL0%3D 10.1111/j.1538-7836.2008.02970.x 18394014 (Pubitemid 351689913)
22. RS Blumenthal B Baranowski SA Dowsett 2004 Cardiovascular effects of raloxifene: the arterial and venous systems Am Heart J 147 5 783 789 1:CAS:528:DC%2BD2cXjsl2gs7w%3D 10.1016/j.ahj.2003.12.019 15131531 (Pubitemid 38880982)
23. E Barrett-Connor KE Ensrud K Harper 2003 Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes Clin Ther 25 3 919 930 1:CAS:528:DC%2BD3sXjsFymurs%3D 10.1016/S0149-2918(03)80114-5 12852708 (Pubitemid 36459698)
24. W De Leo A la Marca G Morgante 2001 Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women Am J Obstet Gynecol 184 3 350 353 10.1067/mob.2001.111065 11228485 (Pubitemid 32206982)
25. BW Walsh LH Kuller RA Wild 1998 Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women JAMA 279 18 1445 1451 1:CAS:528:DyaK1cXjsVOgtLY%3D 10.1001/jama.279.18.1445 9600478 (Pubitemid 28228201)
26. CC Johnston NH Bjarnason FJ Cohen 2000 Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials Arch Intern Med 160 22 3444 3450 1:CAS:528: DC%2BD3MXitFSqsg%3D%3D 10.1001/archinte.160.22.3444 11112238
27. PW Anderson DA Cox A Sashegyi 2001 Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women Maturitas 39 1 71 77 1:CAS:528:DC%2BD3MXltVartrc%3D 10.1016/S0378- 5122(00)00224-3 11451623 (Pubitemid 32635227)
28. PD Delmas NH Bjarnason BH Mitlak 1997 Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women N Engl J Med 337 23 1641 1647 1:CAS:528:DyaK2sXotVSntLw%3D 10.1056/NEJM199712043372301 9385122 (Pubitemid 27510100)
29. C Piperi C Kalofoutis I Lagogianni G Troupis A Kalofoutis 2004 Comparison of raloxifene and atorvastatin effects on serum lipids composition of healthy post-menopausal women Mol Cell Biochem 261 1-2 71 75 1:CAS:528: DC%2BD2cXkt1Wjsb4%3D 10.1023/B:MCBI.0000028739.10079.0b 15362487 (Pubitemid 39004518)
30. E Barrett-Connor L Mosca P Collins MJ Geiger D Grady 2006 Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 355 125 137 1:CAS:528:DC%2BD28Xmsl2ktrs%3D 10.1056/NEJMoa062462 16837676 (Pubitemid 44050394)
31. H Toss B Lindahi A Siegbahn L Wallentin 1997 Prognostic influence of increased fibrinogen and C-reactive proteinlevels in unstable coronary artery disease Circulation 96 4204 4210 1:STN:280:DyaK1c%2Fnsleltw%3D%3D 9416883
32. RP Tracy RN Lemaitre BM Psaty 1997 Relationship of C-reactive protein to risk of cardiovascular disease in the elderly Arterioscler Thromb Vasc Biol 17 1121 1127 1:CAS:528:DyaK2sXktlylu7Y%3D 9194763
33. PM Ridker JE Buring J Shih M Matias CH Hennekens 1998 Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women Circulation 98 731 733 1:CAS:528:DyaK1cXlvVyjtbY%3D 9727541
34. DM Herrington KB Brosnihan BE Pusser 2001 Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women J Clin Endocrinol Metab 86 9 4216 4222 1:CAS:528: DC%2BD3MXmvFCktbg%3D 10.1210/jc.86.9.4216 11549652 (Pubitemid 32848538)
35. BW Walsh S Paul RA Wild 2000 The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial J Clin Endocrinol Metab 85 1 214 218 1:CAS:528:DC%2BD3cXjtl2nsw%3D%3D 10.1210/jc.85.1.214 10634389 (Pubitemid 32268816)
36. A Blum RO Cannon 2001 Selective estrogen receptor modulator effects on serum lipoproteins and vascular function in postmenopausal women and in hypercholesterolemic men Ann N Y Acad Sci 949 168 174 1:CAS:528: DC%2BD38XnsFWqsA%3D%3D 10.1111/j.1749-6632.2001.tb04016.x 11795350
37. GW de Valk-de Roo CD Stehouwer P Meijer 1999 Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study Arterioscler Thromb Vasc Biol 19 12 2993 3000 10591680